Calling Embryo Editing 'Premature,' Russian Authorities Seek to Ease Fears of a Scientist Going Rogue
By Olga Dobrovidova,
STAT
| 10. 16. 2019
MOSCOW — Russian health officials are playing down international concerns that a Moscow researcher plans to create gene-edited babies any time soon, saying for the first time that the experiment would be “premature.”
Denis Rebrikov, the scientist who has said he wants to use the genome-editing technology CRISPR to alter embryos, has sparked widespread alarm among scientists who fear that he could become the second researcher to conduct such work, following the birth of gene-edited twins in China last year.
But in a statement issued last week to Russian wire services, the health ministry here said it fully supports the World Health Organization position against making changes to the human germline — the genome of eggs, sperm, and embryos — that would be inherited by future generations “until its implications have been properly considered.” The ministry said it views any clinical use of genome-editing technologies on human embryos “premature.”
The ministry’s stance puts at least a temporary hurdle in front of Rebrikov, who would need the agency’s approval to proceed with his experiment to repair a mutated gene that causes...
Related Articles
Not the species, certainly, but the Institute of that name, which was founded by transhumanist philosopher Nick Bostrom in 2005 as a research group at Oxford University. According to a recently posted Final Report, its goal was “to pursue the big questions in a transdisciplinary way” by pulling together “researchers from disciplines such as philosophy, computer science, mathematics, and economics.” This evolved before long into the study and promotion of “effective altruism” and “longtermism” as...
By Tristan Manalac, BioSpace | 04.02.2024
Verve Therapeutics has suspended enrollment in the Phase Ib Heart-1 study evaluating its lead gene editing program VERVE-101 following a serious adverse event, the company announced Tuesday.
A patient, who received a 0.45-mg/kg dose of VERVE-101, developed a grade 3...
By Timnit Gebru and Émile P. Torres, First Monday | 04.14.2024
The stated goal of many organizations in the field of artificial intelligence (AI) is to develop artificial general intelligence (AGI), an imagined system with more intelligence than anything we have ever seen. Without seriously questioning whether such a system can...
By Harold Brubaker, The Philadelphia Inquirer | 04.04.2024
Acompany started by University of Pennsylvania scientist Jim Wilson has received FDA approval to test a form of gene editing in infants for the first time in the United States, the company said Thursday.
The Plymouth Meeting company, iECURE, is...